Targeted protein degradation modalities, including PROTACs and molecular glues, have shown increasing maturity with clinical successes such as Arvinas and Pfizer’s vepdegestrant in breast cancer. Despite modest efficacy signals, the field is expanding rapidly with multiple biotechs developing novel degradation platforms to modulate 'undruggable' targets, supported by recent collaborations and investment from large pharmaceutical companies.